Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Equity (2016 - 2025)

Historic Return on Equity for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to 0.91%.

  • Lineage Cell Therapeutics' Return on Equity fell 6000.0% to 0.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.91%, marking a year-over-year decrease of 6000.0%. This contributed to the annual value of 0.26% for FY2024, which is 500.0% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Return on Equity of 0.91% as of Q3 2025, which was down 6000.0% from 0.5% recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Return on Equity registered a high of 0.11% during Q3 2021, and its lowest value of 0.91% during Q3 2025.
  • For the 5-year period, Lineage Cell Therapeutics' Return on Equity averaged around 0.37%, with its median value being 0.34% (2023).
  • Its Return on Equity has fluctuated over the past 5 years, first soared by 3300bps in 2021, then crashed by -6000bps in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Return on Equity (Quarter) stood at 0.4% in 2021, then grew by 12bps to 0.35% in 2022, then rose by 5bps to 0.33% in 2023, then rose by 21bps to 0.26% in 2024, then plummeted by -250bps to 0.91% in 2025.
  • Its Return on Equity stands at 0.91% for Q3 2025, versus 0.5% for Q2 2025 and 0.23% for Q1 2025.